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Figure Legends: 
 
Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Diagram 
to summarise the literature search for this review. 
 
Table Footnotes: 
 
Table 1: Study characteristics of included studies in the Systematic Review. ‘Spinal’ refers to 
measurement of BMD at the lumbar spine. BMD = Bone Mineral Density, aBMD = areal Bone 
Mineral Density. (n) = Number, SC = subcutaneous injection, NS = non-significant, Sig. = 
statistically significant (p<0.05), AN = Anorexia Nervosa, HC = Healthy Controls, BMI = Body Mass 
Index, Tpt = Teriparatide,  EE = Ethinyl Estradiol, ERT = Estrogen Replacement Therapy. NGM = 
Norgestimate, OC = Oral Contraceptives, MED = Menatetrenone. 
 
Table 2: Baseline Participant Characteristics. AN = Anorexia Nervosa, HC = Healthy Controls, BMI 
= Body Mass Index, Tpt = Teriparatide,  EE = Ethinyl Estradiol, ERT = Estrogen Replacement 
Therapy. NGM = Norgestimate, OC = Oral Contraceptives, MED = Menatetrenone.  
 
Supplemental Tables: 
Supplemental Table 1: PRISMA 2009 Checklist 
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Abstract 
Objective: Although there are several evidence-based treatments available to increase Bone Mineral 
Density (BMD) and reduce fracture risk in aging men and women, there are still uncertainties regarding 
which treatments are efficacious in reducing lifetime fracture risk in women with Anorexia Nervosa 
(AN).  
 
Methods: Medline, PsychInfo, Embase and the Cochrane Database were searched for English Language 
Studies. Inclusion criteria were studies of females of any age with AN who received  pharmacological 
treatment with the primary aim to increase BMD or reduce fracture risk. Data were extracted from each 
study regarding pharmacological treatment and dosage used, BMD and bone formation marker 
outcomes; and participant characteristics including age, Body Mass Index (BMI), duration of AN, and 
duration of amenorrhea.  
 
Results: 675 studies were reviewed, of which 19 fit the inclusion criteria and were included in the final 
review, investigating a total of 1119 participants; 10 of the 19 included studies were double-blind RCTs. 
The remaining studies consisted of prospective observational studies, a retrospective cohort study, a 
case-control study and five non-randomised control trials. Bisphosphonates were effective in increasing 
BMD in adult women with AN, while estrogen administered transdermally resulted in significant 
increases in BMD in mature adolescents with AN. Administration of Oral contraceptives (OC) did not 
significantly increase BMD in randomised or controlled trials, however, lifetime OC use was associated 
with higher spinal BMD.  
 
Conclusion: Future research should clarify the safety of long-term bisphosphonate use in adult women 
with AN, and verify that transdermal estrogen replacement increases BMD in women with AN. 
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Introduction 
Eating Disorders 
Eating disorders (ED) are mental health conditions associated with negative outcomes and the highest 
mortality rate among psychiatric disorders [1]. Anorexia Nervosa (AN) and Bulimia Nervosa (BN) are 
the most studied EDs [2] and are associated with both physical and mental co-morbid conditions [3]. 
An important physical co-morbidity is low Bone Mineral Density (BMD), and increased incidence of 
secondary osteoporosis [1, 4].  
 
AN has been associated with low BMD, impaired bone structure and an increased risk of bone fractures 
[3, 5-8].  Fractures are associated with significant pain, disability and loss of work days, and AN patients 
are 7 times more likely to have bone fractures than age-matched healthy women [9]. BMD in AN has 
been found to be reduced by at least 1.0 SD at one or more skeletal sites in 92% of patients and by at 
least 2.5 SD in 38% of adult women with AN in a community sample [10]. Adolescents with AN are 
also at risk for low BMD, with approximately 30% of adolescent girls reporting sustaining a fracture 
[5, 7] and 50% reported to have BMD 1 SD below the mean at one or more skeletal sites [6]. Both 
restricting sub-type (AN-R) and the binge-purge subtype (AN-BP) of AN are associated with reductions 
in spine, hip and limb BMD [11] and increased fracture risk [12]. A recent meta-analysis found normal 
weight women with BN to have spinal BMD significantly lower than healthy control women [13], 
suggesting that weight loss alone may not account for the deleterious effects of an ED on BMD. 
 
Osteoporosis is a condition characterised by skeletal fragility from a decrease in both bone quality and 
quantity. Excessive food restriction and malnutrition in individuals with AN can lead to low BMD and 
secondary osteoporosis at a young age [14]. Weight gain and recovery from AN are known to be the 
strongest predictor of an increase in BMD at all sites, resulting in mean annual increases in BMD of 
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3.1% at the spine and 1.8% at the hip [15]. However, the onset of AN during adolescence can impair 
the acquisition of peak bone mass, resulting in lower BMD throughout adult life [14] and may limit 
increases in BMD following recovery [16]. Of concern, studies in adolescents with AN demonstrate 
that weight gain and menstrual recovery allow for some improvement in bone accrual rates at the spine 
and whole body, but not to the extent observed in normal-weight controls [17]. 
 
BMD and secondary osteoporosis are influenced indirectly by factors such as age, sex, ethnicity, BMI, 
physical activity, muscle function, and calcium and vitamin D intake. Weight-bearing exercise has been 
suggested to have positive effects on BMD, whereas vigorous exercise may have deleterious effects on 
BMD in AN [14]. Smoking and alcohol consumption are known to have a negative effect on both 
directly and indirectly on BMD [18]. Although the risk of fracture cannot be accurately predicted, 
fracture risk of an individual can be inferred through the measurement of BMD using DXA (dual energy 
x-ray absorptiometry) or pQCT (peripheral quantitative computed tomography) in combination with 
clinical features, for example using tools such as the WHO (World Health Organisation) FRAX 
calculator (www. https://www.shef.ac.uk/FRAX/) in older women.  
 
Biochemical bone turnover markers can indicate the efficacy of a treatment in decreasing bone 
resorption or increasing bone formation over time in women with AN in comparison to healthy women. 
These include bone formation markers: osteocalcin (OCN), serum procollagen type I, N-terminal 
propeptide (tP1NP); and, bone resorption markers: serum collagen type I cross-linked C-telopeptide 
(CrossL) and the soluble receptor activator of nuclear factors-κB ligand (sRANKL). The receptor 
activator of nuclear factors-κB ligand (RANKL) is a potent stimulator of bone resorption, operating by 
binding the receptor activator of nuclear factors-κB (RANK) in the cell membrane of osteoclast 
precursors [19]. Adolescents with AN are known to have decreases in biochemical markers of both 
bone formation and resorption, indicative of reduced bone turnover [20, 21],  whereas adults with AN 
have decreased bone formation and increased bone resorption markers, indicative of an uncoupling of 
bone turnover, both of which lead to reductions in BMD [22, 23]. In preliminary treatment trials, 
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markers of bone turnover can be a useful measurement of the potential efficacy of  treatment in 
increasing BMD and reducing fracture risk [24].  
 
The UK-based NICE (National Institute for Health and Care Excellence) guidelines recommend 
bisphosphonates for prevention of fractures in postmenopausal women, but there are no formal 
guidelines to treat low BMD and to prevent fractures in pre-menopausal women with AN [25]. Weight 
gain and the resumption of menstrual function are strong predictors of increased BMD in women with 
AN [24]; however early intervention to prevent the loss of BMD and pharmacological interventions to 
preserve and increase BMD in chronic AN are necessary when low weight and amenorrhea persists 
throughout an ED. For this reason, this review will focus on potential pharmacological treatment 
options for osteoporosis in AN. 
Aim 
The specific aim of the review was to systematically review pharmacological bone active agents that 
increase BMD in women with AN.  
 
Method 
We followed the analytical methods and standards established by the Preferred Reporting Items for 
Systematic Reviews and Meta‐Analyses (PRISMA) group for systematic reviews and meta‐analyses 
[26]. The PICO Framework for using evidence from patient groups (P), the intervention process (I), 
comparison groups (C) and outcomes of an intervention (O) to answer a clinical question was used [27] 
Study Identification 
The search strategy for this review was designed by a University of London librarian and the primary 
reviewer (LR). We searched electronic databases MEDLINE (1), PSYCHInfo (2), EMBASE (3) and Web 
of Science (4). Broadly, the search terms were categorised into three primary areas: (1) Eating Disorders, 
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(2) Risk for Secondary Osteoporosis, and (3) Treatment options. Additional hand searches were 
conducted and reference lists of eligible studies and previous systematic reviews and meta-analyses in 
this area were reviewed. The final literature search was conducted on 3rd March 2017, and this search 
is reported in a PRISMA diagram in Figure 1 and the review was registered with PROSPERO under 
registration number: CRD42015026503.  
 
The search strategy used terms for eating disorders (Anorexia Nervosa* and Eating Disorders*), 
Osteoporosis (Osteoporosis*, Bone Loss*, Bone Density, Bone Mineral Density, Bone Mineral 
Content, Bone Mass, Fracture), and ‘Treatment(s)’. MeSH was used to explore related terms where 
available (*). Related terms explored by MeSH include: ‘Feeding and Eating Disorders’(1,3), ‘Feeding 
and Eating Disorders of Childhood’(1), ‘Bone and Bones’(1,2,3), ‘Bone Resorption’(1,3) and ‘Bone 
Density’(1,2,3), ‘Musculoskeletal system’(2,3) . The search was limited to publications in English. 
< Figure 1 > 
Published articles were eligible if they investigated a treatment to increase BMD in participants with 
AN. Patients with a diagnosis of EDNOS (eating disorder not otherwise specified) or BN were excluded 
due to the lack of available data. Only studies on female participants were included. We did not limit 
inclusion by study type; RCTs (Randomised Control Trials), Controlled Trials, Longitudinal Cohort 
Published studies and one Case Study, with both independent and overlapping samples of participants 
were included in the initial review. Study eligibility was then assessed by two authors (LR and VA) 
who discussed the inclusion criteria and reached a consensus based on the a priori criteria that studies 
report independent samples (no sample is used in multiple reports) of participants with AN and a 
corresponding healthy control group.  
 
The study selection process included initial screening of titles and abstracts against the inclusion criteria 
using EndNote, and screening of full papers against the inclusion criteria. Certain studies that otherwise 
met inclusion criteria were excluded for reasons such as participants with AN being grouped with other 
ED participants. 
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<Figure 1: Flow Diagram of Primary Study selection> 
Inclusion Criteria 
Participants 
Only women with AN who received pharmacological treatment with the primary aim to increase BMD 
or reduce fracture risk were included. There were no restrictions on the current age of participants or 
duration or age of onset of AN. AN was defined according to the DSM-III, DSM-IV or ICD-10 
diagnostic criteria in 15 of 19 studies, with no specified diagnostic criteria in the remaining 4 studies.  
Treatments 
Pharmacological treatments with the aim of increasing BMD and reducing fracture risk in participants 
with AN were included.  
 
Outcome Measures 
Data on BMD, measured by DXA scanning, or fractures were included in this review and any data 
regarding biological markers (described as markers of bone formation, bone metabolism or bone 
regeneration and remodelling markers) were also included as outcome measures in this review.  
Exclusion Criteria 
Studies that solely used psychological or weight-gain oriented interventions were excluded from this 
review, and also those studies which did not include BMD or Bone Metabolism Markers as outcome 
measures were excluded. Studies which investigated mixed ED groups, rather than solely AN 
participants were also excluded.  
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Study Selection 
Two reviewers (LR and VA) independently screened titles and abstracts of eligible studies selected 
using the pre-planned search strategy. The full text of all seemingly eligible studies was evaluated and 
reviewers worked independently to determine their eligibility for the review. Disagreements were 
discussed and resolved.  
Data Collection 
Using a data extraction form designed by the reviewers for the purpose of this study, the reviewers 
extracted data on each of the studies regarding the population studied, the treatment used, and the 
methodology. The BMD data were extracted for pre- and post- treatment where available, and the 
method of measurement was recorded. Authors were contacted if relevant data were missing. 
Covariates 
This review also investigated BMI, age, duration of disorder, comorbid physical conditions, comorbid 
mental health conditions, and duration of amenorrhea in the women in each of the reviewed studies. 
Qualitative assessment investigated trends in the data across the included studies.  
Quality Assessment 
Both reviewers independently assessed the quality of the studies using the EPHPP (Effective Public 
Health Practice Project) quality assessment tool [28], which assesses selection bias, study design, 
confounders, blinding, data collection method, and withdrawals and dropouts. Each study is assigned a 
global rating of strong = 1, moderate = 2 or weak = 3 on Table 1. The two reviewers (LR) (VA) 
highlighted discrepancies in quality rating and ultimately reached an agreement on all assessments. 
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Eight of the included studies received a global assessment of ‘strong’, which indicated that they did 
not receive a ‘weak’ rating on any of the dimensions assessed. The remaining ten studies received a 
‘moderate’ rating, which indicates that they received a ‘weak’ rating on only one of the six study 
dimensions. Quality assessment scores are displayed in Table 1.  
Data extraction and qualitative assessment  
Data was extracted using a pre-designed data extraction form by two reviewers, first piloted using five 
studies to ensure comparable results. Data extracted included age, gender, BMI, menstrual status, 
comorbidities, ethnicity, duration of AN, duration of amenorrhea (both pre- and post-treatment), 
treatment focus and comparator (including type of pharmacological treatment and characteristics of 
comparator treatment), and outcomes (BMD and bone metabolism markers).  
 
The studies were qualitatively compared based on the effect on BMD or biological markers of bone 
metabolism of the treatment investigated. A meta-analysis was not possible due to the heterogeneity in 
the methods used and the treatments investigated across the included studies.  
Grade of Evidence 
Evidence obtained from each study was graded using NICE Guidelines for Anxiety Disorders [29] 
with the WFSBP Guidelines system [30], described by Bandelow et al. (2008) (Table 1).  
 
Results  
Authors reviewed 675 studies and 19 met the inclusion criteria and were included in the final review. 
These included 1119 participants, of which 792 had AN at the time of the treatment and the remainder 
were healthy controls. Table 1 reports the study characteristics for all included studies. Ten of the 
nineteen included studies were double-blind RCTs [31-40]. The remaining studies consisted of 
prospective observational studies [14, 41], a retrospective cohort study [42], a case-control study [43] 
and five non-randomised control trials [23, 44-47]. One study was conducted in Japan [46], one in Spain 
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[45], one in Israel [37] and two in Australia [14, 42] and all other studies were conducted in the USA. 
The mean length of follow-up ranged from 3 months [31] to 34.5 months [41], with the majority of 
studies following participants for at least one year.   
 
Baseline Characteristics 
A total of 399 participants with AN received a treatment aiming to increase BMD, and 379 participants 
with AN received placebo treatment. There were 316 healthy control participants across the studies who 
received no treatment and had no history of an ED. Participants in this review ranged from 11 – 37 
years of age, with a duration of AN ranging from 6.1 months to 6.6 years, and duration of amenorrhea 
ranging from 9.7– 33 months, although amenorrhea duration was not recorded in all studies. All 
included studies investigated women or adolescent girls. The primary source of recruitment was through 
healthcare referrals and advertisements. Baseline characteristics of all participant groups are reported 
in Table 2.  
Weight change and BMI 
Psychological or weight gain interventions reported and conducted alongside those investigated in this 
study are presented in Table 2. Five studies reported significant increases in BMI in participants 
following the study intervention [32, 35, 45, 46, 48], with the remaining studies reporting non-
significant differences or failing to disclose a change in BMI.  
Outcome Measures  
The primary outcome measure was spinal BMD in all but three studies, which measured markers of 
bone metabolism [23, 40]. Secondary outcome measures included hip, femoral neck, radius and total 
body BMD, measures of body composition, and biological markers of bone turnover and fracture 
incidence. All of the included studies used DXA scanning for BMD measures. All studies controlled 
for change in body weight, BMI or body composition when reporting outcome measures. 
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<Table 1> 
<Table 2> 
Bisphosphonates 
Three of the included studies investigated the effect of bisphosphonates on BMD in women with AN; 
two of which investigated the bisphosphonate risedronate in adult women with AN [35, 47] and one 
which investigated alendronate in adolescents with AN [32]. Adolescents with AN failed to demonstrate 
an increase in spinal BMD following 10 mg orally administered alendronate treatment, the site most 
significantly affected in AN [32, 35, 47], though femoral neck BMD did significantly increase following 
one year of treatment. 
 
Risedronate was administered at a dose of either 5 mg orally each day for 9 months [47] or 35 mg orally 
weekly for 12 months and either combined with, or compared to transdermal testosterone [35] in adult 
women with AN. Both studies using risedronate saw a significant increase in spinal BMD (4.9  1% 
and 3.8  1.8%) in participants with AN. When risedronate was compared to transdermal testosterone, 
only risedronate increased BMD and suppressed the bone turnover markers serum c-terminal 
telopeptide (CTX) and procollagen type 1 amino-terminal propeptide (P1NP).  
 
Hormones 
Estrogen  
Oral administration 
Of the seven included studies that measured the effect of estrogen on BMD, one cross-sectional study 
found that AN women who took OCs had on average a higher BMD than those who had never taken 
OCs [14]. One study found significant increases in hip and femoral neck BMD following OC treatment 
(35 g EE; 180 – 250 g Norgestimate) for 13 consecutive 28-day cycles, however, these increases 
were no longer significant after controlling for weight changes [34]. Another study found that when 
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oral contraceptives containing EE (20 g/day) were combined with dehydroepiandrosterone (DHEA 
(50mg/day)), subjects with AN had a stabilisation of femoral neck BMD, compared to a decrease in 
BMD in placebo treated AN women [38]. Two RCTs have shown that EE administered orally in high 
doses (up to 35 µg) for over one year is not effective in increasing BMD in AN [31, 34].  
In contrast to orally administered ethinyl estradiol, physiologic replacement doses of transdermal 17-β 
estradiol, increased spinal and hip BMD in adolescent women with AN [36], although complete ‘catch 
up’ to a comparable BMD in healthy controls did not occur, likely because other hormonal deficits 
persisted [49].  In this RCT, 110 adolescents with AN were randomized to 100 g of 17-β estradiol 
(with cyclic progesterone), low incremental physiological doses of oral EE (3.75 g daily from 0 to 6 
months, 7.5 g from 6 to 12 months, 11.25 g from 12 to 18 months) or placebo for 18 months. These 
physiological doses of estrogen significantly increased spinal and hip BMD in adolescents with AN to 
approximate bone accrual rates in normal-weight healthy controls.   The effect was primarily driven by 
the group receiving transdermal 17-β estradiol. 
 
DHEA 
Three of the included studies measured the effect of DHEA (dehydroepiandrosterone) on BMD, with 
no significant increases in BMD found at any skeletal sites. Two reported an increase in biological 
markers including deoxypiridinolyne (DPD) and osteocalcin following administration of 100 mg of oral 
DHEA daily [37]. Decreases in NTx (N-terminal telopeptide) in response to 50 mg/day of oral DHEA 
in another study [44] indicate a decrease in bone remodelling. DiVasta (2012) combined an oral 
contraceptive with oral DHEA (50mg + 20 g EE /day) and reported a stabilisation of femoral neck 
BMD in the experimental group in comparison to a trend for a decrease in all BMD sites in the AN 
placebo controls [38].  
 
Testosterone 
Although at baseline, levels of testosterone were highly correlated with BMD [35, 50], BMD did not 
increase following transdermal treatment with replacement doses of testosterone (to attain testosterone 
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levels in the upper half of the normal range for women) over 3 weeks or 12 months compared to placebo, 
and markers of bone metabolism did not significantly change either [35, 50].   
 
Teriparatide 
 
Shibli-Rahhal et al. found a  21% increase in BMD and no re-occurrence of fractures following 2 years 
or teriparatide in a 52yr old AN patient [43]. Fazeli et al. investigated the effect of teriparatide (TPT; 
human PTH1-34) (20g/day SC) vs. placebo on BMD, markers of bone metabolism, and IGF-1 in older 
mature women with AN in a randomized controlled trial. They confirmed the findings of Shibi-Rahhal 
et al. and found a 6-10% increase in spine BMD after 6 months of teriparatide and an increase in serum 
P1NP levels in the TPT group [39]. 
 
Recombinant human (rh) IGF-1 
 
RhIGF-1 replacement results in an increase in bone formation markers in both adolescents and adults 
with AN [23, 31, 40]. Furthermore, increases in both spine and hip BMD are found when rhIGF1 is 
combined with an estrogen–progesterone combination pill in a placebo-controlled trial (1.8% ± 0.8% 
vs. -1.0% ± 1.3% at the spine, P < 0.05) [31].  
Nutritional Treatments 
One study investigated the effect of 45 g/day of Menatetrenone (MED) (vitamin K2) on lumbar spine 
BMD over a 9 month follow-up period [46]. BMD decreased in women with AN, but MED slowed the 
decrease in BMD in comparison to placebo controls.  
 
Discussion 
 
Despite there being a well-established treatment regimen to protect and increase BMD and reduce 
fracture incidence in post-menopausal women and older adult males, only nineteen studies investigating 
 15 
pharmacological treatments to increase BMD in women with AN were identified for this review. It was 
not possible to conduct a meta-analysis of results due to the heterogeneity in the research methods and 
methods of treatment, and it was not possible to investigate treatment efficacy in any other EDs due to 
the lack of available data. In order to utilise the available data, the primary outcome measures 
investigated were BMD values measured by DXA scanning, rather than fracture incidence, which may 
be a more clinically relevant measure. We uncovered no RCTs or controlled trials aiming to increase 
BMD in males with AN, despite a new, more gender neutral DSM-5 diagnostic criteria and increasing 
independent data on socioeconomic factors, prenatal influences, clinical characteristics, assessment, 
and mortality for EDs in males [51]. Furthermore, very little evidence of the limitations and potential 
harm caused by long-term use of the treatments investigated in women with AN exists. 
 
A recent meta-analysis suggested that women with AN are likely to have an increased fracture risk of 
150-300 % based on significantly lower BMD values than healthy control women [13]. These women 
present unique challenges in treatment of low bone density as we cannot assume that treatments 
designed to treat the decline in BMD resulting from ageing will be efficacious in this group. 
Furthermore, it is established that weight gain and restoration of menstrual function should be the first 
line of management when treating women with AN [49] although due to the enduring nature of an ED, 
alternative therapies should be available while in pursuit of full recovery. 
 
In adult women, the most significant increases in BMD identified in this review were from 
bisphosphonate therapy [35, 47]. No significant increase in BMD was observed following 
administration of oral contraceptives, transdermal testosterone or oral DHEA alone. Conversely, 100 
g of 17-β estradiol (with cyclic progesterone) administered transdermally did increase spinal and hip 
BMD in mature adolescents with AN [36]. Nutritional treatment, including Vitamin K2 had a beneficial 
effect in reducing the loss of BMD in AN participants, but this effect was not strong enough to entirely 
prevent BMD loss in AN participants over the 9 month trial [46].  
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Pharmacological treatments investigated in this Review 
Bisphosphonates  
 
Bisphosphonates are prescribed to reduce fracture risk in post-menopausal women but have been found 
to have inconsistent benefits in women with AN [32, 35, 47].  
 
Both risedronate and alendronate administered orally resulted in significant increases in BMD at the 
hip [32] and at the spine [35, 47] in adults and adolescents with AN. However, adolescents receiving 
alendronate failed to show BMD increases at the spine [47].  
 
Furthermore, the long-term effects of bisphosphonates are currently unknown and an inadequate 
number of trials exist to confirm their safety. These drugs decrease the activity of the bone-remodelling 
unit, and have the potential to reduce bone modelling and shaping when used over time [32], although 
data to date are reassuring. Oral bisphosphonates have been associated with gastrointestinal distress and 
musculoskeletal pain, which could be exaggerated in AN due to their poor nutritional state and low 
BMI [52].  
 
Although bisphosphonates are effective in increasing BMD, fractures can still occur due to reduced 
tensile strength, possibly resulting from low bone turnover in the restructured bone [53]. For this reason, 
bisphosphonates have been associated with both atypical fractures at the femoral neck with both oral 
and IV administration in adult women [54, 55] and also osteonecrosis of the jaw [56-58], suggesting 
that close monitoring of patients on bisphosphonates is necessary.  
 
Other adverse symptoms include a potential risk to the fetus when bisphosphonates are administered to 
adolescent girls and young adult women of reproductive age, given their long half-life [59], and uveitis, 
thrombocytopenia, or esophageal or oral ulcerations in adults [60]. Although adolescents and adult with 
AN are less likely to become pregnant because of associated hypogonadism, women with a history of 
AN do become pregnant [61]. Bisphosphonates are currently prescribed on a case-by-case basis for 
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premenopausal women, and the US Drug and Food Administration (FDA) has currently only approved 
bisphosphonates for premenopausal women on glucocorticoids [62].   
Hormones 
Estrogen 
 
The revised DSM-5 criteria for AN removed the requirement of amenorrhea, although hypothalamic 
amenorrhea remains to be common among adolescent and adult women with AN. Suppression of the 
hypothamamic-pituitary gonadal axis (HPG) prevents energy from being invested in reproduction in a 
state of semi-starvation [63], and results in estrogen deficiency and varying degrees of menstrual 
dysfunction, the most severe of which is a state of amenorrhea. Despite a similar loss of BMD in AN 
compared to post-menopausal women and a shared feature of increased bone resorption, a significant 
decrease in bone formation is also present in AN  [64] suggesting that factors other than estrogen 
deficiency may also be contributing to low BMD in this condition. These other factors may include 
deficiencies of hormones such as testosterone, DHEA and leptin, and increases in hormones such as 
cortisol and peptide YY [65].  
 
Estrogen receptors are present on both osteoblasts and osteoclasts, and the reduction of circulating 
estrogen resulting from an ED can lead to rapid loss of BMD. Estrogen supplementation has 
antiresorptive effects, increases BMD and reverses the negative calcium balance observed in 
postmenopausal women.  
 
In the included studies, OCs administered in pharmacological doses (20 – 35g EE) resulted in, at best, 
a stabilising effect on bone in RCTs, and on average greater spinal BMD in women with AN who had 
taken OCs compared to those who had not in a retrospective cohort study [14]. However, transdermal 
estradiol administration in physiological doses resulted in an increase in spinal and hip BMD Z-scores 
over 18 months in mature adolescents with AN [36].  
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Although the reasons for the inconsistent benefit on BMD from OCs remain speculative, one hypothesis 
is the suppression of systemic IGF-1 secretion following oral oestrogen administration as is seen in 
post-menopausal women due to a first-pass hepatic effect [66, 67]. Low incremental doses of EE 
administered orally to mimic the early pubertal rise in estrogen may be effective in preserving bone 
mass in young girls who are still growing, as very low oral estrogen doses do not supress IGF-1 [68]. 
Transdermal estrogen, which also does not suppress IGF-1, does increase bone density in adolescents 
with AN [69], although complete ‘catch up’ to a comparable BMD in healthy controls does not occur 
given that other hormonal deficits persist [49].  
 
Testosterone 
 
Older males, and adolescent males with AN [70] have reduced bone density, which is likely from a 
decline in testosterone rather than estrogen [71]. Women with AN also have low testosterone levels, 
which correlate with lower spinal BMD [33]; however, transdermal testosterone administration in 
women with AN resulted in no significant change in osteocalcin and bone-specific alkaline phosphatase 
[33], which are markers of bone formation, and there was no increase in spinal BMD when transdermal 
testosterone was administered without risedronate [35].  
 
Testosterone can be converted to 17 β-estradiol by the P450 aromatase enzyme within bone, and 
subsequently can exert its effects on bone through estrogen receptors: (ER alpha) or P(ERP) [72]. 
Testosterone may also have direct bone anabolic effects and may be beneficial in AN as part of a wider 
hormonal rehabilitation treatment.  
 
DHEA 
 
Suppression of the HPG axis in AN may lead to reduced ovarian DHEA production. Based on available 
studies, this review found no significant effect of DHEA on BMD when administered alone, but a 
stabilisation of femoral neck BMD was observed when it was combined with OCs [73]. DHEA is 
aromatised to weak estrogens by aromatase, and may also have weak bone anabolic effects. 
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Teriparatide 
 
Parathyroid Hormone (PTH) is secreted almost exclusively from the parathyroid gland and is a single 
chain, 84 amino acid polypeptide hormone. Vitamin D deficiency leads to increased production of PTH 
due to its close links with calcium homeostasis, and PTH is also regulated by estrogen [74].  
 
PTH increases osteoblast proliferation and differentiation, and decreases osteoblast apoptosis. 
Teriparatide (TPT; human PTH) has been found to have positive effects on BMD in post-menopausal 
women, and in one pilot RCT, older women with AN showed a significant increase in BMD following 
2 years of teriparatide (TPT; human PTH1-37) administration [39], later supported by a 6 month RCT 
(TPT; human PTH1-34) resulting in significant increases in spinal BMD in adults women with AN [39].  
 
rhIGF-1 
 
rhIGF-1 has been associated with increased bone formation markers in both adults and adolescents with 
AN [23, 40], an increase in bone formation markers, but not BMD when combined with an estrogen-
progesterone combination pill [31]. An ongoing trial at Massachusetts General Hospital (MGH) aims 
to both compare and combine rhIGF1 and transdermal E2 replacement to determine if this treatment 
can enable a ‘catch up’ effect in increasing BMD.  
Vitamin K  
One study in this review investigated Vitamin K-2 supplementation to increase BMD in Japanese 
women with AN and found that Vitamin K-2 supplementation (Menatetrenone) reduced the rate of bone 
loss in AN over a 9 month period, although it was insufficient to cause any increase in BMD [46]. 
Furthermore, vitamin K deficiency was found to be more pronounced in AN binge-purge subtype than 
AN restricting subtype, suggesting that vitamin K deficiency should be compared in other ED subtypes 
and investigated further [75].   
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Alternative Pharmacological Treatments Outside of this Review and Recommendations for 
Future Research 
Oxytocin and Vasopressin 
Oxytocin (OT) and arginine vasopressin (AVP) systems are typically associated with social behaviours. 
However, they are also tightly regulated by estrogen receptors and associated with skeletal homeostasis. 
OT and AVP may be efficacious in increasing BMD in women with AN, but have yet to be investigated 
in an RCT.  
Leptin 
Leptin is a cytokine secreted by adipose tissue that suppresses appetite. It also has a positive impact on 
GnRH pulsatility and may play a role in the onset of puberty. Leptin administration increases levels of 
osteocalcin and bone-specific alkaline phosphatase, which are markers of bone formation, in women 
with hypothalamic amenorrhea. However, this treatment was associated with significant weight loss 
[76], and so would not be a potential treatment for women with AN.  
Selective Estrogen Receptor Modulators  
The FDA has cautioned against use of Selective Estrogen Receptor Modulators (SERMs) in pre-
menopausal women due to a risk to reproductive health, and so no studies have investigated the effect 
of SERMs on bone health in women with AN. However, in postmenopausal women vertebral fracture 
risk was reduced by 30-50% when receiving raloxifene [77], suggesting a promising avenue to 
investigate in women with AN.  
Strontium Ranelate 
Strontium Ranelate is effective in increasing BMD in post-menopausal women [78], however 
restrictions have been placed by the European Medical Agency regarding administration to patients 
with existing heart disease [79]. Based on the association with AN and cardiac and nervous system 
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disturbances [80], this review would not recommend Strontium Ranelate to increase BMD in adults or 
adolescents with AN.  
Nutritional Supplementation 
Calcium 
In women with AN the homeostasis of calcium supply and renewal may be disrupted due to long-term 
malnutrition and disruption of homeostatic functions resulting from a state of semi-starvation [81] . No 
increase in BMD was observed in adolescent girls with AN receiving calcium supplementation [82], 
and a recent meta-analysis has found no association between calcium intake and fracture risk in a health 
population [83]. However, there have been no trials to investigate the effect of calcium food sources on 
BMD rather than calcium supplementation alone [84].  
Vitamin D 
A positive association has been found between serum 25-hydroxy-vitamin D below 50 nmol/l and spinal 
BMD Z-scores in women with AN, and also with increased alkaline phosphatase levels, suggesting an 
adaptive osteoblastic reserve [85].  However, there is no evidence to suggest that calcium or vitamin D 
supplementation increase BMD in AN, and no correlation between calcium or vitamin D intake and 
BMD in adolescents with AN [86].  
Combination Therapies 
Bisphosphonates, estrogen and estrogen agonists/antagonists are antiresorptive medications that slow 
the bone loss that occurs in the breakdown part of the remodelling cycle. Teriparatide (PTH1-34) and 
Natpara (PTH1-84) are anabolic therapies that stimulate bone formation and are currently the only drugs 
of their kind approved for use by the FDA. Combined therapies include combination antiresorptives, 
antiresorptive therapies followed by anabolic therapies, anabolic therapies followed by antiresorptive 
therapies (that take advantage of the bone anabolic window), or combined antiresorptive and anabolic 
therapies. Ettinger et al. found that post-menopausal women treated with alendronate who had 
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previously been administered raloxifene had a rapid increase in BMD, whereas women who had been 
on alendronate and switched to raloxifene showed delays in BMD increase in the spine and a reduction 
in BMD at the hip [77].  
Strengths of this Review 
This comprehensive systematic review summarises the evidence available to date on pharmacological 
treatment of bone loss in subjects with AN, and reviews potential therapeutic strategies to increase 
BMD that have not yet been trialled in AN. Although there will surely be differences in these population 
groups, understanding common mechanisms and responses to treatment can inform both future research 
and clinical practice. Women with AN are often in a state of severe malnutrition, and a greater 
understanding of the mechanisms associated with both anti-resorptive and anabolic therapies, as well 
as supplementation of vitamin D, calcium and vitamin K is vital to ensuring that treatments administered 
to women with EDs are both safe and efficacious.  
Limitations of the Review 
The limitations of the current review centre around the restricted number of studies that have been 
conducted on adolescents and adults with AN with the aim of increasing BMD.   
 
Firstly, women with AN have very low lean and fat mass, which may result in a lower estimate of bone 
mass in a DXA scan. Future research should consider using both DXA scanning to estimate bone mass 
and pQCT (peripheral quantitative CT) scanning to estimate bone size parameters and compartmental 
volumetric BMD. The research investigating the relationship between pharmacological intervention 
and bone health in EDs has focused on DXA scanning results or bone metabolism markers, however 
there is not a direct relationship between biomarkers of bone turnover, BMD and fracture incidence 
[87]. Future research should focus on both BMD change and fracture risk as an outcome measure to 
provide a more clinically relevant estimate of the efficacy of treatment.  
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Too few studies have investigated pharmacological agents to promote an increase in BMD in women 
with AN to accurately predict response to treatments, thus , each patient should be treated on a case-
by-case basis. Furthermore, this review did not find any studies investigating treatments to increase 
BMD in males with ED; therefore, we cannot predict how male ED patients will respond to possible 
treatments.  
 
Several recommendations for future research made in this review are based on research conducted on 
post-menopausal women, but BMD loss in AN is known to be in response to starvation, associated 
estrogen depletion and changes in other hormones that impact bone such as IGF-1 and cortisol. 
Therefore, post-menopausal women may not serve as an appropriate model to predict treatment 
outcomes in AN [88].  
Conclusions 
Although weight restoration may be the most efficacious treatment to regain BMD in AN, the majority 
of the included studies observed non-significant changes in BMI throughout the study duration, 
providing validation for the need of alternative pharmacological interventions for this population.   
 
Evidence suggests that BMD in AN is under tight endocrine control; however, studies in AN (and ED 
in general) targeting specific endocrine hormones that are disrupted are limited. The most common 
form of intervention included estrogen therapy, and the oral route of administration rather than 
transdermal, which has recently been found to be more effective in improving bone density than the 
oral route. Although bisphosphonates are an efficacious treatment in adults with AN, their potential 
side effects in adolescents and pre-menopausal women remain unknown given their long half-life. 
Therefore, treatments to restore hormonal imbalances should be developed in order to both increase 
bone mass and encourage the proper development of bone structure and mechanical strength.  
 
 24 
The positive results derived from preliminary trials administering the 100 mcg transdermal 17-beta 
estradiol patch suggest a promising avenue of future treatment, and warrant further investigation. 
Furthermore, no studies have investigated combination treatments in AN, which may have a greater 
effect on BMD than a single treatment alone.  
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 STUDY PHARMACOLOGICAL 
AGENT  
DOSE TYPE OF 
STUDY 
FOLLOW-UP OUTCOME 
MEASURES 
SIG. CHANGE IN 
OUTCOME 
MEASURE(S) 
QUALITY 
ASSESSMENT 
GRADE OF 
EVIDENCE 
BLOCH 2012 DHEA  
 
100mg/day Double-blind 
placebo controlled 
RCT 
6 months Total body 
Spinal  
Hip 
Femoral Neck 
NS 1 B 
DIVASTA 2012 DHEA  
 
OC: EE/ levonorgestrel  
 
 
50mg 
 
20μg/0.1mg 
Double-blind 
placebo controlled 
RCT 
6, 12 and 18 
months 
Lumbar spine 
Hip 
Whole Body 
Stabilising Effect  2 B 
FAZELI 2014 Teriparatide (TPt) 20μg/day SC Double Blind 
RCT 
3 and 6 months Posteroanterior 
spine 
Lateral Spine 
Hip 
Femoral Neck 
Sig. (spinal only) 1 A 
GOLDEN 2002 OC: EE/progestin  20–35μg EE/day Prospective 
observational 
study 
11.4 - 23.1 
months 
Lumbar spine 
Femoral neck 
NS. 2 C 
GOLDEN 2005 Alendronate  10mg/day Double-blind 
placebo controlled 
RCT 
3, 6, 9 months 
and 1 yr  
Lumbar spine 
Femoral neck 
NS. 2 B 
GORDON 1999 DHEA 50, 100, or 200 
mg/day 
 
Controlled Trial 3 month Lumbar spine 
Total body 
Femoral neck 
NS 2 C 
GRINSPOON 
1996 
rhIGF1 100 or 30μg 
/kg/day 
Controlled Trial 6 days OC 
PICP 
PYRX 
DPYRX 
NTX 
Sig increase in all 
markers (100 μg/day) 
 
Sig, increase in PICP 
only (30 μg/day) 
2 B 
Table 1: Study Characteristics 
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GRINSPOON 
2002 
rhIGF-1  
 
 
EE with rhIGF- 
 
 
 
 
EE+ placebo  
 
30 μg /kg SC 
twice/day 
 
35μg/day 
+ 
30 μg /kg SC 
twice/day 
 
35 μg/day  
Double-blind 
placebo controlled 
RCT 
12 weeks Lateral spine 
BMD 
Hip BMD 
Femoral neck 
BMD 
Total body BMD 
 
NS. 2 B 
IKETANI 2003 MED 45 g/day Controlled trial 0.9 yr  Lumbar spine Stabilizing effect 2 C 
KARLSSON 
2000 
Estrogen Replacement 
Therapy 
 
Various Retrospective 
cohort study 
4.3 yr (1-16yr 
range) 
Lumbar Spine  
Femoral neck  
NS 2 C 
MISRA 2009 RhIGF1 30–40 mcg/k 
twice daily 
Double-blind 
placebo controlled 
RCT 
7-9 days IGF1 
P1NP 
CTX 
Sig. increase in IGF1 
and P1NP 
1 A 
MISRA 2011 Transdermal: 17b-estradiol 
with cyclic 
progesterone 
 
Oral: EE + progesterone 
 
 
100 mg/day 
 
 
 
 
3.75 mg/ 7.5 mg/ 
11.25 mg/ day 
Double-blind 
placebo controlled 
RCT 
18 months Lumbar spine 
Hip  
Sig.  1 A 
MILLER 2011 Risedronate  (R) 
 
Transdermal testosterone 
(T) 
 
Combination  
35mg/week 
 
150 μg/day 
 
R:35mg/week  
T: 150 μg/day 
 
 
Double-blind 
placebo controlled 
RCT 
12 Months Spinal BMD 
 
Hip, and radius 
BMD  
 
Body 
Composition 
Sig. (R) 1 A 
MILLER 2004 
 
 
Risedronate 5mg/day  Controlled trial 6 Months, 9 
Months 
Spinal BMD Sig. 1 A 
 32 
MILLER 2005 Transdermal testosterone 
 
150μg/ 
300μg/day  
Double-blind 
placebo controlled 
RCT 
3 week  Spinal BMD NS 1 B 
MUNOZ 2002 OC: EE 30  μg/day 
 
 
Controlled trial 12 months Spinal BMD 
 
NS 2 C 
SEEMAN 1992 OC: Various Various 
 
 
 
Prospective 
observational 
study 
61 months ± 9% 
duration of 
illness. 
Spinal BMD 
Femoral Neck 
BMD 
Sig. (spinal) 2 C2 
SHIBLI-
RAHHAL 2012 
Teriparatide (TPt) 20 mcg/day 
 
 
 
Case Study 2 years Lumbar spine 
Femoral neck 
Sig. 2 D 
STROKOSCH 
2006 
OC: Norgestimate (NGM)  
 
OC: EE  
180 – 250μg/day 
 
35μg/day 
Double-blind 
placebo controlled 
RCT 
13 consecutive 
28 day cycles 
Lumbar spine 
BMD 
NS. 1 B 
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Study Groups N Age  
(Mean 
Baseline) 
M BMI 
Pre 
(kg/m2) 
Duration of 
Amenorrhea  
(months) 
Duration 
of 
AN  
(months) 
Diagnostic  
Criteria 
Weight Gain 
Strategies 
Change in BMI or 
Weight 
Bloch 2012 AN - DHEA  
AN - Placebo  
15 
11 
26.6 17.75   DSM-IV Ongoing psychotherapy which 
included weekly individual dynamic 
psychotherapy and group 
cognitive/supportive psychotherapy 
+ nutritional assessment 
 
NS change in BMI 
DiVasta 
2012 
AN - DHEA + 
OC 
AN - Placebo  
31 
 
29 
18  
18.3   
18.1  
17.8  
11 12  Participants were enrolled in 
outpatient therapy for an ED at 
Boston children’s hospital.   
 
Among trial completers, 
5 lost weight (1.4-5.3 
kg), 1 subject showed no 
change, and the 
remainder gained up to 
21.7 kg. 
 
Fazeli 2014 AN – TPT 
AN – Placebo 
10 
11 
47 
47 
17.6 
16.6 
N = 8 
N = 7 
292.8 
216 
   
Golden 
2002 
AN – 
EE/progestin 
AN – 
Treatment 
controls 
22 
28 
 
17.5  
16.3  
 
17.1 
16.7 
16.5 29.8 DSM-IV All subjects were in outpatient 
treatment for EDs.  
 
 
Golden 
2005 
AN - 
Alendronate 
AN - Placebo 
15 
17 
16.9 
16.9 
16.3 
16.4 
20.1 
19.9 
25.7 
34.7 
DSM-IV  15 of 29 subjects 
achieved a weight 85% 
of standard body weight 
Gordon 
1999 
AN - DHEA 15 17.3 17.3 20.9 29.1 DSM-IV Subjects enrolled in ED program in 
Boston Children’s Hospital  
 
NS change in BMI 
Grinspoon 
1996 
AN- rhIGF1 
100 μg 
23 23 16.3 22 60 DSM-IV  NS change in BMI 
Table 2: Participant Characteristics 
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AN- rhIGF1 
30 μg 
Grinspoon 
2002 
AN - rhIGF-1 
AN - Placebo 
29 
30 
25.6 16.9 
16.3 
  DSM-IV  NS change in BMI 
Iketani 
2003 
AN – MED + 
AN – MED -  
HC 
10 
11 
12 
22.1 
21.3 
22.2 
13.6 
13.7 
19.6 
3.6 yr 
3.5 yr. 
3.9 yr 
4.1 yr. 
DSM-IV   Sig. increase in BMI in 
both groups, no 
differences between 
groups 
Karlsson 
2000 
AN – ERT 
AN – No 
treatment 
AN - 
Recovered 
HC 
58 
77 
26 
205 
 
28.4 
25.9 
27.3 
27.3 
15.4 
15.6 
20.3 
23.1 
 4.5 yr 
5.4 yr. 
3.5yr. 
ICD-10   
Misra 2009 AN – rhIGF1 
AN – Placebo 
10 
10 
16.2 
16.3 
17.2 
17.5 
 6.1 
9 
DSM-IV   NS change in BMI 
Misra 2011 AN – E+ 
AN – E- 
HC 
31 
30 
29 
16.5 
 
15.6 
17.4 
 
21.4 
0.9yr  DSM-IV All girls with AN were under the 
care of multidisciplinary treatment 
teams organized by their primary 
providers.  
 
 
Miller 2011 AN – 
Risedronate-
Testosterone 
AN – 
Risedronate 
AN – 
Testosterone 
AN - Placebo 
20 
20 
19 
18 
25.2 
25.3 
27.1 
26.9 
17.8 
17.6 
17.5 
17.9 
 6.3 
5.1 
6.6 
5.2 
DSM-IV  Sig increases in weight 
in both groups, no 
differences across 
groups.  
Miller 2004 AN – 
Risedronate  
AN - control 
10 
14 
28.6  
26.9 
44kg 
42 kg 
33 
23  
 DSM-IV  No sig increase in BMI 
in exp group, but control 
group BMI sig. increased 
at 9 months (p<0.01) 
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Miller 2005 AN – 
Testosterone  
AN - Placebo 
24 
9 
25 
22 
16.9 
16.6 
 
  DSM-IV  NS change in BMI 
Munoz – 
Cavalo 
2007 
AN – E+ 
AN – E- 
HC 
10 
10 
19  
15.4      Sig. increase in BMI in 
Group 2 (patients with 
AN for < 1 yr.) 
 
Seeman 
1992 
AN OC 
AN OC- 
HC 
Primary 
amenorrhea 
37  
16  
52  
12  
24.4 17.2 +- 
0.8 
 66.5 +- 
15.5 
DSM- III- 
R 
 NS difference in BMI 
across groups (cross-
sectional) 
Shibli-
Rahhal 
2012 
AN TPt 1 52 14.3 4 yr 72   Weight restored prior to 
treatment. NS change in 
BMI following TPt. 
 
Strokosch 
2006 
AN - NGM/EE 
AN - Placebo 
53 
59 
15.2 
15.1 
17.94 
 
9.7 (m)  DSM-IV  NS change in BMI 
